The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Scientific expertise and technical know-how across a broad range of relevant techniques, such as cell culture, cellular pharmacology, biochemical assays, molecular biology, receptor pharmacology, enzymology, protein-based assays, imaging-based assays, and biophysical approaches including SPR.